Credit Suisse’s Oruka Therapeutics ORKA Stock Holding History

Credit Suisse’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-93	Closed	-$11K	–	4031
2018 Q2	$11K	Hold	93	–	–	﹤0.01%	3937
2018 Q1	$10K	Buy	+93	New	+$25K	﹤0.01%	3939

Other funds holding ORKA

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACP

Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse's ORKA Position: Q3 2018 in Review

Credit Suisse sold out of Oruka Therapeutics (ORKA) in Q3 2018, closing a stake of 93 shares — an estimated $11K sold.

Credit Suisse first reported a position in ORKA in Q1 2018 and held it in 2 quarters. The position peaked at $11K in Q2 2018. 12 funds tracked by Wall St. Rank hold ORKA as of Q3 2018.

Credit Suisse reported no remaining Oruka Therapeutics position as of Q3 2018 after selling out during the quarter.
Credit Suisse sold 93 Oruka Therapeutics shares in Q3 2018, an estimated $11K.
Credit Suisse first reported a position in Oruka Therapeutics in Q1 2018 and held it in 2 quarters.
Credit Suisse's Oruka Therapeutics position peaked at $11K in Q2 2018.
12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2018.

Based on Credit Suisse's 13F filing for Q3 2018, filed 13 Nov 2018.